Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2010, Article ID 863985, 13 pages
http://dx.doi.org/10.1155/2010/863985
Review Article

Controlling Influenza by Cytotoxic T-Cells: Calling for Help from Destroyers

1Department for Molecular Biomedical Research, VIB, 9052 Ghent, Belgium
2Department of Biomedical Molecular Biology, Ghent University, 9052 Ghent, Belgium

Received 17 December 2009; Accepted 3 March 2010

Academic Editor: Zhengguo Xiao

Copyright © 2010 Michael Schotsaert et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Kresse and H. Rovini, “Influenza vaccine market dynamics,” Nature Reviews Drug Discovery, vol. 8, no. 11, pp. 841–842, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. A. E. Fiore, C. B. Bridges, and N. J. Cox, “Seasonal influenza vaccines,” Current Topics in Microbiology and Immunology, vol. 333, pp. 43–82, 2009. View at Google Scholar
  3. S. E. Hensley, S. R. Das, A. L. Bailey et al., “Hemagglutinin receptor binding avidity drives influenza a virus antigenic drift,” Science, vol. 326, no. 5953, pp. 734–736, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Banzhoff, M. Pellegrini, G. Del Giudice, E. Fragapane, N. Groth, and A. Podda, “MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis,” Influenza and Other Respiratory Viruses, vol. 2, no. 6, pp. 243–249, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. I. Leroux-Roels, F. Roman, S. Forgus et al., “Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study,” Vaccine, vol. 28, no. 3, pp. 849–857, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Morein, B. Sundquist, S. Hoglund, K. Dalsgaard, and A. Osterhaus, “Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses,” Nature, vol. 308, no. 5958, pp. 457–460, 1984. View at Google Scholar · View at Scopus
  7. G. F. Rimmelzwaan, N. Nieuwkoop, A. Brandenburg et al., “A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOMTM vaccines and conventional vaccines,” Vaccine, vol. 19, no. 9-10, pp. 1180–1187, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Mullbacher, G. L. Ada, and R. Hla, “Gamma-irradiated influenza A virus can prime for a cross-reactive and cross-protective immune response against influenza A viruses,” Immunology and Cell Biology, vol. 66, no. 2, pp. 153–157, 1988. View at Google Scholar · View at Scopus
  9. A. Mullbacher, M. Lobigs, M. Alsharifi, and M. Regner, “Cytotoxic T-cell immunity as a target for influenza vaccines,” The Lancet Infectious Diseases, vol. 6, no. 5, pp. 255–256, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. A. T. Heiny, O. Miotto, K. N. Srinivasan et al., “Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets,” PLoS ONE, vol. 2, no. 11, article e1190, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Neirynck, T. Deroo, X. Saelens, P. Vanlandschoot, W. M. Jou, and W. Fiers, “A universal influenza A vaccine based on the extracellular domain of the M2 protein,” Nature Medicine, vol. 5, no. 10, pp. 1157–1163, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Matsui, S. Kohyama, T. Suda et al., “A CTL-based liposomal vaccine capable of inducing protection against heterosubtypic influenza viruses in HLA-A*0201 transgenic mice,” Biochemical and Biophysical Research Communications, vol. 391, no. 3, pp. 1494–1499, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Mozdzanowska, J. Feng, M. Eid et al., “Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2,” Vaccine, vol. 21, no. 19-20, pp. 2616–2626, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. A. M. Frace, A. I. Klimov, T. Rowe, R. A. Black, and J. M. Katz, “Modified M2 proteins produce heterotypic immunity against influenza A virus,” Vaccine, vol. 17, no. 18, pp. 2237–2244, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. S. M. Tompkins, Z.-S. Zhao, C.-Y. Lo et al., “Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1,” Emerging Infectious Diseases, vol. 13, no. 3, pp. 426–435, 2007. View at Google Scholar · View at Scopus
  16. J. B. Ulmer, J. J. Donnelly, S. E. Parker et al., “Heterologous protection against influenza by injection of DNA encoding a viral protein,” Science, vol. 259, no. 5102, pp. 1745–1749, 1993. View at Google Scholar · View at Scopus
  17. T.-M. Fu, L. Guan, A. Friedman et al., “Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge,” Journal of Immunology, vol. 162, no. 7, pp. 4163–4170, 1999. View at Google Scholar · View at Scopus
  18. J. R. Bennink, J. W. Yewdell, G. L. Smith, and B. Moss, “Anti-influenza virus cytotoxic T lymphocytes recognize the three viral polymerases and a nonstructural protein: responsiveness to individual viral antigens is major histocompatibility complex controlled,” Journal of Virology, vol. 61, no. 4, pp. 1098–1102, 1987. View at Google Scholar · View at Scopus
  19. W. Fiers, M. De Filette, K. E. Bakkouri et al., “M2e-based universal influenza A vaccine,” Vaccine, vol. 27, no. 45, pp. 6280–6283, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. D. M. Brown, A. M. Dilzer, D. L. Meents, and S. L. Swain, “CD4 T cell-mediated protection from lethal influenza: perform and antibody-mediated mechanisms give a one-two punch,” Journal of Immunology, vol. 177, no. 5, pp. 2888–2898, 2006. View at Google Scholar · View at Scopus
  21. S. D. Norton, L. Zuckerman, K. B. Urdahl, R. Shefner, J. Miller, and M. K. Jenkins, “The CD28 ligand, B7, enhances IL-2 production by providing a costimulatory signal to T cells,” Journal of Immunology, vol. 149, no. 5, pp. 1556–1561, 1992. View at Google Scholar · View at Scopus
  22. R. B. Belshe, “Current status of live attenuated influenza virus vaccine in the US,” Virus Research, vol. 103, no. 1-2, pp. 177–185, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. T. J. Powell, T. Strutt, J. Reome et al., “Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus,” Journal of Immunology, vol. 178, no. 2, pp. 1030–1038, 2007. View at Google Scholar · View at Scopus
  24. L. Shen and K. L. Rock, “Priming of T cells by exogenous antigen cross-presented on MHC class I molecules,” Current Opinion in Immunology, vol. 18, no. 1, pp. 85–91, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Sawai, Y. Itoh, H. Ozaki et al., “Induction of cytotoxic T-lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin,” Immunology, vol. 124, no. 2, pp. 155–165, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Sette and J. Sidney, “Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism,” Immunogenetics, vol. 50, no. 3-4, pp. 201–212, 1999. View at Google Scholar · View at Scopus
  27. N. L. La Gruta, K. Kedzierska, K. Pang et al., “A virus-specific CD8+ T cell immunodominance hierarchy determined by antigen dose and precursor frequencies,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 4, pp. 994–999, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. R. G. van der Most, K. Murali-Krishna, J. G. Lanier et al., “Changing immunodominance patterns in antiviral CD8 T-cell responses after loss of epitope presentation or chronic antigenic stimulation,” Virology, vol. 315, no. 1, pp. 93–102, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Liu, B. A. Ewald, D. M. Lynch, A. Nanda, S. M. Sumida, and D. H. Barouch, “Modulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies,” Journal of Virology, vol. 80, no. 24, pp. 11991–11997, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. J. H. C. M. Kreijtz, R. Bodewes, G. van Amerongen et al., “Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice,” Vaccine, vol. 25, no. 4, pp. 612–620, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Bodewes, J. H. C. M. Kreijtz, C. Baas et al., “Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus,” PLoS ONE, vol. 4, no. 5, article e5538, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Tschernig and R. Pabst, “Bronchus-associated lymphoid tissue (BALT) is not present in the normal adult lung but in different diseases,” Pathobiology, vol. 68, no. 1, pp. 1–8, 2000. View at Google Scholar · View at Scopus
  33. J. E. Moyron-Quiroz, J. Rangel-Moreno, K. Kusser et al., “Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity,” Nature Medicine, vol. 10, no. 9, pp. 927–934, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. C. H. Geurtsvankessel, M. A. M. Willart, I. M. Bergen et al., “Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice,” Journal of Experimental Medicine, vol. 206, no. 11, pp. 2339–2349, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Vujanic, J. L. K. Wee, K. J. Snibson et al., “Combined mucosal and systemic immunity following pulmonary delivery of ISCOMATRIXTM adjuvanted recombinant antigens,” Vaccine, vol. 28, no. 14, pp. 2593–2597, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. B. Lowin, M. Hahne, C. Mattmann, and J. Tschopp, “Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways,” Nature, vol. 370, no. 6491, pp. 650–652, 1994. View at Publisher · View at Google Scholar · View at Scopus
  37. D. J. Topham, R. A. Tripp, and P. C. Doherty, “CD8+ T cells clear influenza virus by perform or Fas-dependent processes,” Journal of Immunology, vol. 159, no. 11, pp. 5197–5200, 1997. View at Google Scholar · View at Scopus
  38. R. M. Zinkernagel, “On natural and artificial vaccinations,” Annual Review of Immunology, vol. 21, pp. 515–546, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. R. A. Seder, J.-L. Boulay, F. Finkelman et al., “CD8+ T cells can be primed in vitro to produce IL-4,” Journal of Immunology, vol. 148, no. 6, pp. 1652–1656, 1992. View at Google Scholar · View at Scopus
  40. M. Croft, L. Carter, S. L. Swain, and R. W. Dutton, “Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles,” Journal of Experimental Medicine, vol. 180, no. 5, pp. 1715–1728, 1994. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Hamada, M. D. L. L. Garcia-Hernandez, J. B. Reome et al., “Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge,” Journal of Immunology, vol. 182, no. 6, pp. 3469–3481, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. A. E. Oran and H. L. Robinson, “DNA vaccines: influenza virus challenge of a Th2/Tc2 immune response results in a Th2/Tc1 response in the lung,” Journal of Virology, vol. 78, no. 8, pp. 4376–4380, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Sun, R. Madan, C. L. Karp, and T. J. Braciale, “Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10,” Nature Medicine, vol. 15, no. 3, pp. 277–284, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. K. K. McKinstry, T. M. Strutt, A. Buck et al., “IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge,” Journal of Immunology, vol. 182, no. 12, pp. 7353–7363, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. F. Castellino, P. E. Boucher, K. Eichelberg et al., “Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways,” Journal of Experimental Medicine, vol. 191, no. 11, pp. 1957–1964, 2000. View at Publisher · View at Google Scholar · View at Scopus
  46. A. A. R. Tobian, C. V. Harding, and D. H. Canaday, “Mycobacterium tuberculosis heat shock fusion protein enhances class I MHC cross-processing and -presentation by B lymphocytes,” Journal of Immunology, vol. 174, no. 9, pp. 5209–5214, 2005. View at Google Scholar · View at Scopus
  47. G. Ikonomidis, Y. Paterson, F. J. Kos, and D. A. Portnoy, “Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes,” Journal of Experimental Medicine, vol. 180, no. 6, pp. 2209–2218, 1994. View at Publisher · View at Google Scholar · View at Scopus
  48. P. Q. Hu, R. J. Tuma-Warrino, M. A. Bryan et al., “Escherichia coli expressing recombinant antigen and listeriolysin O stimulate class I-restricted CD8+ T cells following uptake by human APC,” Journal of Immunology, vol. 172, no. 3, pp. 1595–1601, 2004. View at Google Scholar · View at Scopus
  49. S. De Koker, B. G. De Geest, S. K. Singh et al., “Polyelectrolyte microcapsules as antigen delivery vehicles to dendritic cells: uptake, processing, and cross-presentation of encapsulated antigens,” Angewandte Chemie International Edition, vol. 48, no. 45, pp. 8485–8489, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Shen, A. L. Ackerman, V. Cody et al., “Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles,” Immunology, vol. 117, no. 1, pp. 78–88, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Heit, F. Schmitz, M. O'Keeffe et al., “Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines,” Journal of Immunology, vol. 174, no. 7, pp. 4373–4380, 2005. View at Google Scholar · View at Scopus
  52. D. J. Shedlock and H. Shen, “Requirement for CD4 T cell help in generating functional CD8 T cell memory,” Science, vol. 300, no. 5617, pp. 337–339, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. J. T. Harty and V. P. Badovinac, “Shaping and reshaping CD8+ T-cell memory,” Nature Reviews Immunology, vol. 8, no. 2, pp. 107–119, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Mullbacher, “The long-term maintenance of cytotoxic T cell memory does not require persistence of antigen,” Journal of Experimental Medicine, vol. 179, no. 1, pp. 317–321, 1994. View at Publisher · View at Google Scholar · View at Scopus
  55. K. Murali-Krishna, L. L. Lau, S. Sambhara, F. Lemonnier, J. Altman, and R. Ahmed, “Persistence of memory CD8 T cells in MHC class I-deficient mice,” Science, vol. 286, no. 5443, pp. 1377–1381, 1999. View at Publisher · View at Google Scholar · View at Scopus
  56. F. Sallusto, J. Geginat, and A. Lanzavecchia, “Central memory and effector memory T cell subsets: function, generation, and maintenance,” Annual Review of Immunology, vol. 22, pp. 745–763, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. F. Sallusto, D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia, “Two subsets of memory T lymphocytes with distinct homing potentials and effector functions,” Nature, vol. 401, no. 6754, pp. 708–712, 1999. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Sambhara, S. Woods, R. Arpino et al., “Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes,” Journal of Infectious Diseases, vol. 177, no. 5, pp. 1266–1274, 1998. View at Google Scholar · View at Scopus
  59. G. F. Rimmelzwaan and G. Sutter, “Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara,” Expert Review of Vaccines, vol. 8, no. 4, pp. 447–454, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. G. Sutter and B. Moss, “Nonreplicating vaccinia vector efficiently expresses recombinant genes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 22, pp. 10847–10851, 1992. View at Publisher · View at Google Scholar · View at Scopus
  61. J. A. Wolff, R. W. Malone, P. Williams et al., “Direct gene transfer into mouse muscle in vivo,” Science, vol. 247, no. 4949, part 1, pp. 1465–1468, 1990. View at Google Scholar · View at Scopus
  62. J. J. Donnelly, J. B. Ulmer, J. W. Shiver, and M. A. Liu, “DNA vaccines,” Annual Review of Immunology, vol. 15, pp. 617–648, 1997. View at Google Scholar
  63. H. W. Temin, “Overview of biological effects of addition of DNA molecules to cells,” Journal of Medical Virology, vol. 31, no. 1, pp. 13–17, 1990. View at Publisher · View at Google Scholar · View at Scopus
  64. J. A. Wolff, J. J. Ludtke, G. Acsadi, P. Williams, and A. Jani, “Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle,” Human Molecular Genetics, vol. 1, no. 6, pp. 363–369, 1992. View at Google Scholar · View at Scopus
  65. H. A. Smith, “Regulatory considerations for nucleic acid vaccines,” Vaccine, vol. 12, no. 16, pp. 1515–1519, 1994. View at Publisher · View at Google Scholar · View at Scopus
  66. J. S. Robertson, “Safety considerations for nucleic acid vaccinese,” Vaccine, vol. 12, no. 16, pp. 1526–1528, 1994. View at Publisher · View at Google Scholar · View at Scopus
  67. P. J. M. Openshaw and J. S. Tregoning, “Immune responses and disease enhancement during respiratory syncytial virus infection,” Clinical Microbiology Reviews, vol. 18, no. 3, pp. 541–555, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. W. Huisman, B. E. E. Martina, G. F. Rimmelzwaan, R. A. Gruters, and A. D. M. E. Osterhaus, “Vaccine-induced enhancement of viral infections,” Vaccine, vol. 27, no. 4, pp. 505–512, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. R. H. Mealey, S. R. Leib, M. H. Littke, B. Wagner, D. W. Horohov, and T. C. McGuire, “Viral load and clinical disease enhancement associated with a lentivirus cytotoxic T lymphocyte vaccine regimen,” Vaccine, vol. 27, no. 18, pp. 2453–2468, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. J. Simeckova-Rosenberg, Z. Yun, P. R. Wyde, and M. Zouhair Atassi, “Protection of mice against lethal viral infection by synthetic peptides corresponding to B- and T-cell recognition sites of influenza A hemagglutinin,” Vaccine, vol. 13, no. 10, pp. 927–932, 1995. View at Publisher · View at Google Scholar · View at Scopus
  71. D. Moskophidis and D. Kioussis, “Contribution of virus-specific CD8+ cytotoxic T cells to virus clearance or pathologic manifestations of influenza virus infection in a T cell receptor transgenic mouse model,” Journal of Experimental Medicine, vol. 188, no. 2, pp. 223–232, 1998. View at Publisher · View at Google Scholar · View at Scopus
  72. J. S. Haring, V. P. Badovinac, and J. T. Harty, “Inflaming the CD8+ T cell response,” Immunity, vol. 25, no. 1, pp. 19–29, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. K. M. Grebe, H. D. Hickman, K. R. Irvine, K. Takeda, J. R. Bennink, and J. W. Yewdell, “Sympathetic nervous system control of anti-influenza CD8+ T cell responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 13, pp. 5300–5305, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. J. M. Moffat, T. Gebhardt, P. C. Doherty, S. J. Turner, and J. D. Mintern, “Granzyme a expression reveals distinct cytolytic CTL subsets following influenza A virus infection,” European Journal of Immunology, vol. 39, no. 5, pp. 1203–1210, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. S. S. Metkar, C. Menaa, J. Pardo et al., “Human and mouse granzyme A induce a proinflammatory cytokine response,” Immunity, vol. 29, no. 5, pp. 720–733, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. N. L. La Gruta, K. Kedzierska, J. Stambas, and P. C. Doherty, “A question of self-preservation: immunopathology in influenza virus infection,” Immunology and Cell Biology, vol. 85, no. 2, pp. 85–92, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. G. F. Rimmelzwaan, A. C. M. Boon, J. T. M. Voeten, E. G. M. Berkhoff, R. A. M. Fouchier, and A. D. M. E. Osterhaus, “Sequence variation in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes,” Virus Research, vol. 103, no. 1-2, pp. 97–100, 2004. View at Publisher · View at Google Scholar · View at Scopus
  78. E. G. M. Berkhoff, M. M. Geelhoed-Mieras, M. Jonges et al., “An amino acid substitution in the influenza A virus hemagglutinin associated with escape from recognition by human virus-specific CD4+ T-cells,” Virus Research, vol. 126, no. 1-2, pp. 282–287, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. B. Korber, M. LaBute, and K. Yusim, “Immunoinformatics comes of age,” PLoS Computational Biology, vol. 2, no. 6, article e71, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. B. Peters, J. Sidney, P. Bourne et al., “The immune epitope database and analysis resource: from vision to blueprint,” PLoS Biology, vol. 3, no. 3, article e91, 2005. View at Google Scholar
  81. R. Vita, L. Zarebski, J. A. Greenbaum et al., “The immune epitope database 2.0,” Nucleic Acids Research, vol. 38, supplement 1, pp. D854–D862, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. N. Salimi and R. Vita, “The biocurator: connecting and enhancing scientific data,” PLoS Computational Biology, vol. 2, no. 10, article e125, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. R. Vita, K. Vaughan, L. Zarebski et al., “Curation of complex, context-dependent immunological data,” BMC Bioinformatics, vol. 7, article 341, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. B. Peters and A. Sette, “Integrating epitope data into the emerging web of biomedical knowledge resources,” Nature Reviews Immunology, vol. 7, no. 6, pp. 485–490, 2007. View at Publisher · View at Google Scholar · View at Scopus
  85. H.-H. Bui, B. Peters, E. Assarsson, I. Mbawuike, and A. Sette, “Ab and T cell epitopes of influenza A virus, knowledge and opportunities,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 1, pp. 246–251, 2007. View at Publisher · View at Google Scholar · View at Scopus
  86. J. A. Greenbaum, M. F. Kotturi, Y. Kim et al., “Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 48, pp. 20365–20370, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. S. Stevanovic, “Antigen processing is predictable: from genes to T cell epitopes,” Transplant Immunology, vol. 14, no. 3-4, pp. 171–174, 2005. View at Publisher · View at Google Scholar · View at Scopus
  88. J. C. Tong, T. W. Tan, and S. Ranganathan, “Methods and protocols for prediction of immunogenic epitopes,” Briefings in Bioinformatics, vol. 8, no. 2, pp. 96–108, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. V. Brusic, V. B. Bajic, and N. Petrovsky, “Computational methods for prediction of T-cell epitopes—a framework for modelling, testing, and applications,” Methods, vol. 34, no. 4, pp. 436–443, 2004. View at Publisher · View at Google Scholar · View at Scopus
  90. C. Lundegaard, O. Lund, C. Kesmir, S. Brunak, and M. Nielsen, “Modeling the adaptive immune system: predictions and simulations,” Bioinformatics, vol. 23, no. 24, pp. 3265–3275, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. H. H. Lin, S. Ray, S. Tongchusak, E. L. Reinherz, and V. Brusic, “Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research,” BMC Immunology, vol. 9, article 8, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. L. Moise and A. S. De Groot, “Putting immunoinformatics to the test,” Nature Biotechnology, vol. 24, no. 7, pp. 791–792, 2006. View at Publisher · View at Google Scholar · View at Scopus
  93. M. Moutaftsi, B. Peters, V. Pasquetto et al., “A consensus epitope prediction approach identifies the breadth of murine TCD8+-cell responses to vaccinia virus,” Nature Biotechnology, vol. 24, no. 7, pp. 817–819, 2006. View at Publisher · View at Google Scholar · View at Scopus
  94. C. Lundegaard, M. Nielsen, and O. Lund, “The validity of predicted T-cell epitopes,” Trends in Biotechnology, vol. 24, no. 12, pp. 537–538, 2006. View at Publisher · View at Google Scholar · View at Scopus
  95. A. S. De Groot, M. Ardito, E. M. McClaine, L. Moise, and W. D. Martin, “Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-2009 conventional influenza vaccine,” Vaccine, vol. 27, no. 42, pp. 5740–5747, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. I. A. Doytchinova and D. R. Flower, “Class I T-cell epitope prediction: improvements using a combination of proteasome cleavage, TAP affinity, and MHC binding,” Molecular Immunology, vol. 43, no. 13, pp. 2037–2044, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. G. L. Zhang, N. Petrovsky, C. K. Kwoh, J. T. August, and V. Brusic, “PRED(TAP): a system for prediction of peptide binding to the human transporter associated with antigen processing,” Immunome Research, vol. 2, article 3, 2006. View at Google Scholar
  98. V. Brusic, J. T. August, and N. Petrovsky, “Information technologies for vaccine research,” Expert Review of Vaccines, vol. 4, no. 3, pp. 407–417, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. J. C. Tong and E. C. Ren, “Immunoinformatics: current trends and future directions,” Drug Discovery Today, vol. 14, no. 13-14, pp. 684–689, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. J. E. McElhaney, D. Xie, W. D. Hager et al., “T cell responses are better correlates of vaccine protection in the elderly,” Journal of Immunology, vol. 176, no. 10, pp. 6333–6339, 2006. View at Google Scholar · View at Scopus
  101. J. E. McElhaney, C. Ewen, X. Zhou et al., “Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults,” Vaccine, vol. 27, no. 18, pp. 2418–2425, 2009. View at Publisher · View at Google Scholar · View at Scopus
  102. D. M. Carragher, D. A. Kaminski, A. Moquin, L. Hartson, and T. D. Randall, “A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus,” Journal of Immunology, vol. 181, no. 6, pp. 4168–4176, 2008. View at Google Scholar · View at Scopus
  103. G. F. Rimmelzwaan, R. A. Fouchier, and A. D. Osterhaus, “Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development,” Current Opinion in Biotechnology, vol. 18, no. 6, pp. 529–536, 2007. View at Publisher · View at Google Scholar · View at Scopus
  104. G. F. Rimmelzwaan and J. E. McElhaney, “Correlates of protection: novel generations of influenza vaccines,” Vaccine, vol. 26, supplement 4, pp. D41–D44, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. A. J. McMichael, F. M. Gotch, G. R. Noble, and P. A. S. Beare, “Cytotoxic T-cell immunity to influenza,” New England Journal of Medicine, vol. 309, no. 1, pp. 13–17, 1983. View at Google Scholar · View at Scopus
  106. T. Sonoguchi, H. Naito, and M. Hara, “Cross-subtype protection in humans during sequential, overlapping, and/or concurrent epidemics caused by H3N2 and H1N1 influenza viruses,” Journal of Infectious Diseases, vol. 151, no. 1, pp. 81–88, 1985. View at Google Scholar · View at Scopus
  107. S. L. Epstein, “Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature,” Journal of Infectious Diseases, vol. 193, no. 1, pp. 49–53, 2006. View at Publisher · View at Google Scholar · View at Scopus
  108. J. Jameson, J. Cruz, M. Terajima, and F. A. Ennis, “Human CD8+ and CD4+ T lymphocyte memory to influenza a viruses of swine and avian species,” Journal of Immunology, vol. 162, no. 12, pp. 7578–7583, 1999. View at Google Scholar · View at Scopus
  109. A. C. M. Boon, G. De Mutsert, D. Van Baarle et al., “Recognition of homo- and heterosubtypic variants of influenza A viruses by human CD8+ T lymphocytes,” Journal of Immunology, vol. 172, no. 4, pp. 2453–2460, 2004. View at Google Scholar · View at Scopus
  110. J. H. C. M. Kreijtz, G. De Mutsert, C. A. Van Baalen, R. A. M. Fouchier, A. D. M. E. Osterhaus, and G. F. Rimmelzwaan, “Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus,” Journal of Virology, vol. 82, no. 11, pp. 5161–5166, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. G. F. Rimmelzwaan, J. H. C. M. Kreijtz, R. Bodewes, R. A. M. Fouchier, and A. D. M. E. Osterhaus, “Influenza virus CTL epitopes, remarkably conserved and remarkably variable,” Vaccine, vol. 27, no. 45, pp. 6363–6365, 2009. View at Publisher · View at Google Scholar · View at Scopus
  112. D. L. Bolton and M. Roederer, “Flow cytometry and the future of vaccine development,” Expert Review of Vaccines, vol. 8, no. 6, pp. 779–789, 2009. View at Publisher · View at Google Scholar · View at Scopus
  113. J. E. McElhaney, S. Gravenstein, C. M. Upshaw et al., “Granzyme B: a marker of risk for influenza in institutionalized older adults,” Vaccine, vol. 19, no. 27, pp. 3744–3751, 2001. View at Publisher · View at Google Scholar · View at Scopus
  114. C. Ewen, K. P. Kane, I. Shostak et al., “A novel cytotoxicity assay to evaluate antigen-specific CTL responses using a colorimetric substrate for Granzyme B,” Journal of Immunological Methods, vol. 276, no. 1-2, pp. 89–101, 2003. View at Publisher · View at Google Scholar · View at Scopus
  115. B. Z. Packard and A. Komoriya, “Intracellular protease activation in apoptosis and cell-mediated cytotoxicity characterized by cell-permeable fluorogenic protease substrates,” Cell Research, vol. 18, no. 2, pp. 238–247, 2008. View at Publisher · View at Google Scholar · View at Scopus
  116. K. T. Brunner, J. Mauel, J. C. Cerottini, and B. Chapuis, “Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs,” Immunology, vol. 14, no. 2, pp. 181–196, 1968. View at Google Scholar · View at Scopus
  117. A. Chahroudi, G. Silvestri, and M. B. Feinberg, “Measuring T cell-mediated cytotoxicity using fluorogenic caspase substrates,” Methods, vol. 31, no. 2, pp. 120–126, 2003. View at Publisher · View at Google Scholar · View at Scopus
  118. K. R. Jerome, D. D. Sloan, and M. Aubert, “Measurement of CTL-induced cytotoxicity: the caspase 3 assay,” Apoptosis, vol. 8, no. 6, pp. 563–571, 2003. View at Publisher · View at Google Scholar · View at Scopus
  119. C. A. van Baalen, R. A. Gruters, E. G. M. Berkhoff, A. D. M. E. Osterhaus, and G. F. Rimmelzwaan, “FATT-CTL assay for detection of antigen-specific cell-mediated cytotoxicity,” Cytometry Part A, vol. 73, no. 11, pp. 1058–1065, 2008. View at Publisher · View at Google Scholar · View at Scopus
  120. K. Chen, L. Chen, P. Zhao et al., “FL-CTL assay: fluorolysometric determination of cell-mediated cytotoxicity using green fluorescent protein and red fluorescent protein expressing target cells,” Journal of Immunological Methods, vol. 300, no. 1-2, pp. 100–114, 2005. View at Publisher · View at Google Scholar · View at Scopus
  121. D. L. Barber, E. J. Wherry, and R. Ahmed, “Cutting edge: rapid in vivo killing by memory CD8 T cells,” Journal of Immunology, vol. 171, no. 1, pp. 27–31, 2003. View at Google Scholar · View at Scopus
  122. K. M. Grebe, J. W. Yewdell, and J. R. Bennink, “Heterosubtypic immunity to influenza A virus: where do we stand?” Microbes and Infection, vol. 10, no. 9, pp. 1024–1029, 2008. View at Publisher · View at Google Scholar · View at Scopus
  123. R. Bodewes, J. H. Kreijtz, and G. F. Rimmelzwaan, “Yearly influenza vaccinations: a double-edged sword?” The Lancet Infectious Diseases, vol. 9, no. 12, pp. 784–788, 2009. View at Publisher · View at Google Scholar · View at Scopus
  124. L. Corbeel, “Should healthy children be vaccinated against influenza? Comments about this query,” European Journal of Pediatrics, vol. 166, no. 6, pp. 629–631, 2007. View at Publisher · View at Google Scholar · View at Scopus
  125. T. Heikkinen, R. Booy, M. Campins et al., “Should healthy children be vaccinated against influenza? A consensus report of the Summits of Independent European Vaccination Experts,” European Journal of Pediatrics, vol. 165, no. 4, pp. 223–228, 2006. View at Publisher · View at Google Scholar · View at Scopus
  126. L. Moral and E. M. Rubio, “We will have to vaccinate healthy children against influenza when we know that it is helpful,” European Journal of Pediatrics, vol. 165, no. 11, p. 817, 2006. View at Publisher · View at Google Scholar · View at Scopus
  127. T. Heikkinen and V. Peltola, “Influenza vaccination of children,” The Lancet Infectious Diseases, vol. 9, no. 12, pp. 720–721, 2009. View at Publisher · View at Google Scholar · View at Scopus
  128. A. S. De Groot, “Immunomics: discovering new targets for vaccines and therapeutics,” Drug Discovery Today, vol. 11, no. 5-6, pp. 203–209, 2006. View at Publisher · View at Google Scholar · View at Scopus
  129. A. Sette and B. Peters, “Immune epitope mapping in the post-genomic era: lessons for vaccine development,” Current Opinion in Immunology, vol. 19, no. 1, pp. 106–110, 2007. View at Publisher · View at Google Scholar · View at Scopus
  130. E. Stern, E. R. Steenblock, M. A. Reed, and T. M. Fahmy, “Label-free electronic detection of the antigen-specific T-cell immune response,” Nano Letters, vol. 8, no. 10, pp. 3310–3314, 2008. View at Publisher · View at Google Scholar · View at Scopus
  131. Y. Soen, D. S. Chen, D. L. Kraft, M. M. Davis, and P. O. Brown, “Detection and characterization of cellular immune responses using peptide-MHC microarrays,” PLoS Biology, vol. 1, no. 3, article E65, 2003. View at Publisher · View at Google Scholar · View at Scopus